Sanofi Board Forces Out CEO Chris Viehbacher Amid Lantus Woes
This article was originally published in The Tan Sheet
Executive Summary
Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.
You may also be interested in...
Sanofi Creates Consumer Unit With Eye To Expansion
Former Bayer executive Alan Main tapped to lead Consumer HealthCare global business unit, which Sanofi will consider expanding through acquisitions after integrating OTC brands added in a recent swap with Boehringer Ingelheim.
Sanofi Creates Consumer Unit With Eye To Expansion
Former Bayer executive Alan Main tapped to lead Consumer HealthCare global business unit, which Sanofi will consider expanding through acquisitions after integrating OTC brands added in a recent swap with Boehringer Ingelheim.
Sanofi Adds Consumer Brands, Grows Footprint With Boehringer Ingelheim Deal
BI international brands including Mucoangin cough suppressant and Dulcolax constipation treatment and US heartburn remedy Zantac would join Sanofi's consumer portfolio including US brands Allegra Allergy antihistamines and Nasacort Allergy 24HR nasal decongestant in the firm's proposed asset swap.